It was reported that the patient presented with st elevation myocardial infarction (stemi) and the procedure was to treat a chronic totally occluded, de novo lesion in the proximal left anterior descending (lad) artery with mild calcification.A 3.0 x 48 mm xience xpedition stent was implanted without any issues noted.The patient was compliant with dual antiplatelet drug therapy (dapt) and was fine post procedure.The next day, the patient suddenly developed ventricular tachycardia (vt) and intubation was done immediately followed by cardiopulmonary resuscitation (cpr); however, the patient experienced cardiac arrest and died.The cause of death reported was cardiac arrest.No additional information was provided.
|
(b)(4).There was no reported device malfunction and the product was not returned.The reported patient effects of death and ventricular tachycardia, as listed in the xience xpedition everolimus eluting coronary stent system instructions for use (ifu) are known patient effects that may be associated with use of a coronary stent in native coronary arteries.Although a conclusive cause for the reported patient effects, and the relationship to the product, if any, cannot be determined, there is no indication of a product quality issue with respect to manufacturing, design or labeling.The xience xpedition 48 is currently not commercially available in the u.S.However, it is similar to a device sold in the u.S.
|